Feasibility of beta-particle radioguided surgery for a variety of "nuclear medicine" radionuclides. (November 2017)

• Record Type: Journal Article
• Authors: Mancini-Terracciano, Carlo; Donnarumma, Raffaella; Bencivenga, Gaia; Bocci, Valerio; Cartoni, Antonella; Collamati, Francesco; Fratoddi, Ilaria; Giordano, Alessandro; Indovina, Luca; Maccora, Daria; Marafini, Michela; Mirabelli, Riccardo; Morganti, Silvio; Rotili, Dante; Russomando, Andrea; Scotognella, Teresa; Solfaroli Camillocci, Elena; Toppi, Marco; Traini, Giacomo; Venditti, Iole; Faccini, Riccardo
• Is Part Of: Physica medica. Volume 43(2017)
• Page Start: 127
• Page End: 133
• Publication Date: 2017-11
• Subjects: Radioguided-surgery -- Brain tumors -- β decays -- Intraoperative imaging; Medical physics -- Periodicals; Biophysics -- Periodicals; Biophysics -- Periodicals; Imagerie médicale -- Périodiques; Radiothérapie -- Périodiques; Rayons X -- Sécurité -- Mesures -- Périodiques; Physique -- Périodiques; Médecine -- Périodiques; 610.153
• DOI: 10.1016/j.ejmp.2017.10.012
• Languages: English
• ISSNs: 1120-1797

Abstract

Highlights: The β - radio-guided surgery (RGS) overcomes the limitations of the γ RGS. Nowadays the only β - radio-nuclide (RN) available is 90 Y. We measured the probe prototype efficiency to several radioactive sources. With such measures we benchmarked the Monte Carlo simulation (MC) of our probe. With the MC we evaluated the RGS feasibility with RNs used in medicine besides 90 Y. Abstract: Purpose: Beta-particle radioguided tumor resection may potentially overcome the limitations of conventional gamma-ray guided surgery by eliminating, or at least minimizing, the confounding effect of counts contributed by activity in adjacent normal tissues. The current study evaluates the clinical feasibility of this approach for a variety of radionuclides. Nowadays, the only β - radioisotope suited to radioguided surgery is 90 Y. Here, we study the β - probe prototype capability to different radionuclides chosen among those used in nuclear medicine. Methods: The counting efficiency of our probe prototype was evaluated for sources of electrons and photons of different energies. Such measurements were used to benchmark the Monte Carlo (MC) simulation of the probe behavior, especially the parameters related to the simulation of the optical photon propagation in the scintillation crystal. Then, the MC simulation was used to derive the signal and the background we would measure from a small tumor embedded in the patient body if one of the selected radionuclides is used. Results: Based on the criterion of detectability of a 0.1 ml tumor for a counting interval of 1 s and an administered activity of 3 MBq/kg, the current probe yields a detectable signal over a wide range of Standard Uptake Values (SUVs) and tumor-to-non-tumor activity-concentration ratios (TNRs) for 31 Si, 32 P, 97 Zr, and 188 Re. Although efficient counting of 83 Br, 133 I, and 153 Sm proved somewhat more problematic, the foregoing criterion can be satisfied for these isotopes as well for sufficiently high SUVs and TNRs.